New eye injection aims to control wet AMD with fewer doses
Disease control
Not yet recruiting
This early-stage study tests the safety of an experimental drug called EYC-0305 in 30 adults aged 50 and older with wet age-related macular degeneration (AMD). Participants receive an injection into the eye every 24 weeks. The goal is to see if the drug is safe and tolerable, and…
Phase: PHASE1, PHASE2 • Sponsor: Eyconis INC. • Aim: Disease control
Last updated May 20, 2026 11:57 UTC